Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...
Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...
Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Class of<br />
<strong>Drug</strong><br />
A2RB (ANGIOTENSIN 2 RECEPTOR<br />
BLOCKERS)<br />
14<br />
Substrate<br />
class<br />
<strong>Drug</strong> Brand name (non<br />
exhaustive list,<br />
generics not listed).<br />
For a complete list,<br />
please consult<br />
www.bcfi.be or<br />
www.cbip.be<br />
Liverpool University (*) /<br />
Extra-information<br />
Candesartan Atacand ® , Atacand Plus ® No information<br />
available but<br />
interaction<br />
unlikely<br />
Eprosartan Teveten ® , Teveten Plus ® No information<br />
available but<br />
interaction<br />
unlikely<br />
Irbesartan Aprovel ® , Co-Aprovel ® No information<br />
available<br />
Olmesartan Olmetec ® , Belsar ® ,<br />
Olmetec Plus ® , Belsar<br />
Plus ® , Forzaten ® , Forzaten<br />
/ HCT ® , Sevikar ® , Sevikar<br />
/ HCT ®<br />
Telmisartan Micardis ® , Kinzalmono ® ,<br />
Micardis Plus ® ,<br />
Kinzalkomb ® , Twynsta ®<br />
Losartan Cozaar ® , Loortan ® , Cozaar<br />
Plus ® , Loortan Plus ®<br />
Valsartan Diovan ® , Co-Diovane ® ,<br />
Exforge ® , Exforge HCT ®<br />
No information<br />
available but<br />
interaction<br />
unlikely<br />
No information<br />
available but<br />
interaction<br />
unlikely<br />
Not clinically<br />
significant<br />
No information<br />
available but<br />
interaction<br />
unlikely<br />
Recommendations SmPC/<br />
Scientific Literature<br />
Dose reduction could<br />
be considered for<br />
irbesartan in patients<br />
initiating BOC k<br />
Dose reduction could<br />
be considered for<br />
losartan in patients<br />
initiating BOC k<br />
Kiser et al., hepatology<br />
2012: contribution of CYP3A4<br />
in the metabolism of A2RB<br />
irbesartan and losartan. Dose<br />
reduction could be considered<br />
for irbesartan and losartan in<br />
patients initiating BOC<br />
CYP pathway(s)<br />
(www.cbip/bcfi.be)<br />
(www.mims.com.au)<br />
CYP2C9<br />
CYP2C9<br />
CYP3A4<br />
Substrate/<br />
Inhibitor/<br />
Inducer
Change language